{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Evaluating",
    "query": {
      "condition": "Evaluating"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 6232,
    "total_pages": 624,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Evaluating&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T15:48:12.089Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05433896",
      "title": "Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics",
        "Drug Interactions"
      ],
      "interventions": [
        {
          "name": "Dasatinib ASD",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole 40 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xspray Pharma AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 17,
      "start_date": "2020-11-01",
      "completion_date": "2020-12-19",
      "has_results": false,
      "last_update_posted_date": "2022-06-27",
      "last_synced_at": "2026-06-25T15:48:12.089Z",
      "location_count": 1,
      "location_summary": "Dilworth, Minnesota",
      "locations": [
        {
          "city": "Dilworth",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05433896"
    },
    {
      "nct_id": "NCT05628688",
      "title": "A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of Insight® Pro Device for Evaluating Lymphatic and Venous Disorders (VOLGA)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lymphedema",
        "Chronic Venous Insufficiency",
        "Edema",
        "Venous Insufficiency of Leg"
      ],
      "interventions": [
        {
          "name": "Insight Pro Device for Diagnosis",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Koya Medical, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2023-08-08",
      "completion_date": "2025-12-04",
      "has_results": false,
      "last_update_posted_date": "2025-12-12",
      "last_synced_at": "2026-06-25T15:48:12.089Z",
      "location_count": 1,
      "location_summary": "Oakland, California",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05628688"
    },
    {
      "nct_id": "NCT01844739",
      "title": "A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "NVN1000 4% Gel",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novan, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2013-04",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2018-11-19",
      "last_synced_at": "2026-06-25T15:48:12.089Z",
      "location_count": 1,
      "location_summary": "Broomall, Pennsylvania",
      "locations": [
        {
          "city": "Broomall",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01844739"
    },
    {
      "nct_id": "NCT07135401",
      "title": "Optimizing Liver MRI Using Breath-Holding With and Without Oxygen",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "MRI",
        "MRI Image Enhancement"
      ],
      "interventions": [
        {
          "name": "Breath-hold conditions",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2025-12-01",
      "completion_date": "2026-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-06-25T15:48:12.089Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07135401"
    },
    {
      "nct_id": "NCT07513181",
      "title": "Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ulcerative Colitis",
        "Inflammatory Bowel Diseases",
        "Autoimmune Diseases"
      ],
      "interventions": [
        {
          "name": "ATH-063",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Athos Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 120,
      "start_date": "2026-06",
      "completion_date": "2028-12-14",
      "has_results": false,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-06-25T15:48:12.089Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Roswell, Georgia",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Roswell",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07513181"
    },
    {
      "nct_id": "NCT00245271",
      "title": "Safety of OMS103HP in Patients Undergoing Anterior Cruciate Ligament (ACL) Reconstruction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anterior Cruciate Ligament Reconstruction"
      ],
      "interventions": [
        {
          "name": "OMS103HP",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Omeros Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "17 Years to 65 Years"
      },
      "enrollment_count": 480,
      "start_date": "2004-10",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2011-06-27",
      "last_synced_at": "2026-06-25T15:48:12.089Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Redwood City, California • Denver, Colorado + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00245271"
    },
    {
      "nct_id": "NCT02770170",
      "title": "Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lupus Nephritis"
      ],
      "interventions": [
        {
          "name": "BI 655064 dose 1",
          "type": "DRUG"
        },
        {
          "name": "BI 655064 dose 2",
          "type": "DRUG"
        },
        {
          "name": "BI 655064 dose 3",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 121,
      "start_date": "2016-05-16",
      "completion_date": "2020-08-18",
      "has_results": true,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-06-25T15:48:12.089Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Doral, Florida • Kissimmee, Florida + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02770170"
    },
    {
      "nct_id": "NCT04736173",
      "title": "Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Nonsquamous Non Small Cell Lung Cancer",
        "Squamous Non Small Cell Lung Cancer",
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Domvanalimab",
          "type": "DRUG"
        },
        {
          "name": "Zimberelimab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arcus Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 169,
      "start_date": "2021-02-08",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-06-25T15:48:12.089Z",
      "location_count": 3,
      "location_summary": "Columbus, Georgia • Kingwood, Texas • Blacksburg, Virginia",
      "locations": [
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Kingwood",
          "state": "Texas"
        },
        {
          "city": "Blacksburg",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04736173"
    },
    {
      "nct_id": "NCT05206370",
      "title": "A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Smoking Cessation"
      ],
      "interventions": [
        {
          "name": "Cytisinicline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Behavioral support",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Achieve Life Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 792,
      "start_date": "2022-01-20",
      "completion_date": "2023-03-21",
      "has_results": true,
      "last_update_posted_date": "2026-01-14",
      "last_synced_at": "2026-06-25T15:48:12.089Z",
      "location_count": 12,
      "location_summary": "DeLand, Florida • Fort Myers, Florida • Jacksonville, Florida + 9 more",
      "locations": [
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Oak Brook",
          "state": "Illinois"
        },
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05206370"
    },
    {
      "nct_id": "NCT02694770",
      "title": "A Study Evaluating the Efficacy and Safety of Neihulizumab vs \"Conventional Treatment\" to Treat Sr-aGvHD",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation"
      ],
      "interventions": [
        {
          "name": "Neihulizumab Treatment",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Conventional Treatment",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AbGenomics B.V Taiwan Branch",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2016-07",
      "completion_date": "2018-02",
      "has_results": false,
      "last_update_posted_date": "2016-04-25",
      "last_synced_at": "2026-06-25T15:48:12.089Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • Seattle, Washington",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02694770"
    }
  ]
}